Internet Breakthrough: Ahammune Biosciences Secures Funding For Vitiligo Treatment
Ahammune Biosciences Secures Funding for Vitiligo Treatment
Pune-based biotech startup, Ahammune Biosciences, has successfully raised $5 Mn in its Series A funding round, led by pi Ventures. This financial backing will significantly support the company as it embarks on the second phase of human clinical trials for its innovative drug candidate targeting vitiligo.
Investment Round Overview
- This funding round attracted notable participation from:
- Capital2B
- Colossa Ventures
- Bipin Agarwal and Unicornus Maximus
- Existing investors including Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and IAN.
The funds raised will also be allocated towards enhancing the patent portfolio and advancing research and development for other immune-mediated skin conditions.
Innovative Approach in Vitiligo Treatment
Founded in 2016 by Dr. Parul Ganju and Dr. Krishnamurthy Natarajan, Ahammune remains at the forefront of developing cutting-edge therapies for chronic skin diseases. The startup's small molecule drug candidate offers a novel approach, avoiding generalised immunosuppression and boasting a first-in-class mechanism of action.
Its unique capability to halt the spread of vitiligo patches while actively stimulating color-producing cells in the skin represents a significant advancement in treatment methodologies, with the potential for repigmentation.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.